The Filing Desk

Alumis vs Verastem

Alumis ALMS · Verastem VSTM · Pharmaceuticals

Verastem reported revenue of $31 million in fiscal 2025, 1.3 times Alumis' $24 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -550.3% at Verastem.

Side by side

AlumisVerastem
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$24M$31M
Revenue growth—209.1%
Revenue growth a year, last 5 years—−19.0%
Gross margin——
Operating margin−1,886.9%−550.3%
Net margin−1,011.8%−677.6%
Free cash flow−$370M—
Free cash flow margin−1,539.2%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count200.0%94.1%
Last close$5.60$8.18
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlumisVerastem
Operating margin
Percent of revenue
AlumisVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisVerastem

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and Verastem pages.